Alladapt Immunotherapeutics Funding: $179M Raised, Series C
Alladapt Immunotherapeutics is based in Menlo Park, California. It has raised $179M in total funding. Latest round: Series C.
Alladapt Immunotherapeutics funding overview
Alladapt Immunotherapeutics is based in Menlo Park, California. Alladapt Immunotherapeutics has raised $179M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series C announced in June 2022. The round record for Alladapt Immunotherapeutics runs through 2022; nothing later has been disclosed. Investors on record include Enavate Sciences, Gurnet Point Capital, Allerfund, Novartis, Red Tree Venture Capital, WestRiver Group. 6 distinct backers are named across the disclosed rounds.
Alladapt Immunotherapeutics at a glance
Total raised
$179M
Latest round
Series C
Latest round date
June 2022
Headquarters
Menlo Park, California
Notable investors
Enavate Sciences, Gurnet Point Capital, Allerfund, Novartis, Red Tree Venture Capital, WestRiver Group
Frequently asked about Alladapt Immunotherapeutics funding
How much has Alladapt Immunotherapeutics raised?
Alladapt Immunotherapeutics has raised $179M in total disclosed funding across the rounds on record.
Who has invested in Alladapt Immunotherapeutics?
Enavate Sciences, Gurnet Point Capital, Allerfund, Novartis, Red Tree Venture Capital, WestRiver Group are named among the investors backing Alladapt Immunotherapeutics.
What was the latest Alladapt Immunotherapeutics funding round?
The most recent disclosed round is a Series C, announced in June 2022.
Where is Alladapt Immunotherapeutics based?
Alladapt Immunotherapeutics is based in Menlo Park, California.
When did Alladapt Immunotherapeutics last raise?
The last disclosed Alladapt Immunotherapeutics round closed in June 2022 at Series C.
Alladapt Immunotherapeutics totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related companies in Menlo Park below to benchmark round size and investor mix.
Companies related to Alladapt Immunotherapeutics (25)
